Patient-derived science
for patient-centred progress
Advanced mitochondrial and cellular compound screening that combines fully-phenotyped, patient-derived cell models with world-leading scientific expertise.
Discover what’s possible
Human-centric modelling
We use patient-derived fibroblasts, neurons and astrocytes for high-fidelity, disease-relevant modelling.
Specialist compound testing
We can quantify 100+ physiological and mitochondrial parameters and accurately screen 900 candidates per 1536-well plate.
Expert interpretation
We combine world-leading mitochondrial and cellular expertise with rigorous scientific interpretation.
Disease-relevant research
We work across Parkinson’s, Alzheimer’s and rare diseases, with models available for disease-relevant research.
Complex biology
clearer decisions
Patient-derived models reveal a more complete picture of cellular health. But data alone isn’t enough.
Mitotype uses cutting-edge high-throughput compound testing technologies, highly translatable patient-derived cell models, and comprehensive mitochondrial and cellular analysis to de-risk discovery and help you transform your complex data into confident drug development decisions.
Specialist support
shaped around your project
Our state-of-the-art mitochondrial compound screening techniques have been honed over the last decade to enable rapid identification of effective compounds, saving you time and money at all stages of preclinical discovery.
Patients are at the heart of everything we do. Mitotype is deeply
committed to delivering consistent, high-quality science to accelerate the development and availability of effective treatments for people living with conditions that are currently incurable.
Our services
Drug discovery screening
We deliver rapid, high-throughput evaluation in patient-derived cells to identify promising candidates and reveal potential toxicity earlier.
⟶
Lead validation and optimisation
We use bespoke, multiplexed assays that measure disease-relevant pathways and targets to distinguish meaningful leads and understand how they perform.
⟶
Cellular and mitochondrial toxicity
We measure disease-relevant pathways across mitochondrial, lysosomal and protein-aggregation biology, with patient-derived models accessible and ready for testing.
⟶
Biomarkers and clinical support
We offer specialist insight to identify relevant biomarkers and biological parameters that can strengthen trial design and future clinical development.
⟶How we work
Bespoke scientific solutions
confident, evidence-led decisions
Every project begins with a different biological question. Mitotype works collaboratively to design the right approach, generate meaningful evidence and translate the findings into a clear way forward.
01
Understand the challenge
Your programme, scientific question and the decision you need to make.
02
Shape the right approach
Relevant, validated patient models, assays and measures selected around your project.
03
Generate meaningful evidence
Specialist mitochondrial compound screening and rigorous analysis reveal a fuller biological picture.
04
Turn insight
into direction
World-leading expertise, interpretation and recommendations help you decide what comes next.
About Mitotype
World-leading science
a deeply human purpose
Mitotype was founded by mitochondrial biology pioneer Professor Heather Mortiboys, with a clear ambition: to use patient-derived biology to improve how promising therapeutics are identified and advanced.
Built on more than a decade of pioneering research, we combine scientific rigour with a deep commitment to patient benefit.
Client perspectives
What set them apart from other CROs in the PD space was that the cell lines they could access represented a different model — and the experience of deriving and characterising those models shone through our interactions.
Vad Lazari
VP Biology, NRG Therapeutics
